AzureCell Therapies key facts
- Developer of regenerative therapies designed to restore neural function and address neurodegeneration through engineered cell integration.
- It has raised $1.3M; the latest was Early Stage VC in Dec 2025.
- Notable investors include MassChallenge, Venture Kick, Innosuisse, Kickfund, Swissnex — 7 tracked in total.
- Status: Privately Held (backing).
Who backs AzureCell Therapies
7- ·Watch AzureCell Therapies: the Monday email on marks, rounds and moves
AzureCell Therapies funding rounds
No funding rounds for AzureCell Therapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AzureCell Therapies investors
7 investors are on record for AzureCell Therapies, including MassChallenge, Venture Kick, Innosuisse and Kickfund.
About AzureCell Therapies
Developer of regenerative therapies designed to restore neural function and address neurodegeneration through engineered cell integration. The company offers lab-grown neurons from donor stem cells with controlled production, safety features, and long-term brain compatibility, enabling healthcare providers to deliver consistent treatments for neurological conditions such as Parkinson's disease with reduced risk and improved therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2024
- Employees
- 4
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AzureCell Therapies doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.